Next Generation GM Oncolytic Viruses
GeneMedicine is actively developing patent-protected, next-generation oncoltyc virus(OV) piplines via innovative technologies: 1) development and construction of various OVs, 2) targeting of multiple cancer signaling pathways through the insertion of therapeutic genes, and 3) development of systemically administerable OVs.
GeneMedicine has four potent OV pipelines and the platform technology.
1) GM101 has successfully completed phase 1 trial against solid tumors. Phase 2 trial is expected to begin by 2022. In phase 1 trial, GM101 induced regression of both primary and metastatic tumors.
2) GM102 targets intractable pancreatic cancer. Phase I trial is expected to begin in 2022. GM102 specializes in destruction of tumor ECM. It creates strong anti-metastatic effect in hypoxic TME.
3) GM103 targets metastatic lung and liver cancer. It is expected to enter clinical trial by 2022. GM103 is designed to induce potent antitumor immune response and anti-angiogenic effect in the tumor vasculature, making it a promising candidate to treat both primary and metastatic tumors.
4) GM104 transforms so-called cold tumors(poorly immunogenic or non-immunogenic tumors) into hot tumors by inflaming tumor-infiltrating lymphocytes within TME. GM104 expresses three therapeutic transgenes that either promote ECM degradation or induce strong antitumor immune response, allowing it to effectively overcome the challenges of immunosuppression and physical barriers of TME.
5) GM platform technology employs tumor-targeted nanotechnology as a systemic carrier for our pipelines. It exponentially increases intratumoral accumulation of viruses upon systemic administration while attenuating nonspecific sequestration into normal tissues, thus leading to superior therapeutic efficacy as well as safety profile. Furthermore, our nanomaterial-based systemic delivery enables OVs to efficiently evade host immune system. This contributes to much longer blood retention of OVs....
More Info Less Info